Ariela Noy MD

PubMed

• Mutational and copy number analysis at diagnosis and relapse of mantle cell lymphoma.
  Erel Joffe, Manik Uppal, Serena Zheng, Kurt S Bantilan, Connie Batlevi
  Haematologica. 2025-11-27
• Novel devimistat results in complete remissions in heavily pretreated Burkitt lymphoma in a phase 2 trial.
  Raphael Steiner, Liana Nikolaenko, Ranjit Nair, Venkatraman Seshan, Swetha Kambhampati Thiruvengadam
  Blood Advances. 2025-11-11
• Methylation-specific qPCR for the EBV C promoter to quantify EBV methylation.
  Logan George, Paul G Rubinstein, Jennifer Petr, Ariela Noy, Lisa Haley
  Infectious Agents and Cancer. 2025-10-30

Abstracts/Posters

• MSKCC Early Experience Using Radiotherapy As a Bridging Strategy for Relapsed Diffuse Large B Cell Lymphoma before CD19 CAR T Therapy
  Ariela Noy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Comparative Analysis of Immune Reconstitution in HIV-Positive Recipients of Allogeneic and Autologous Stem Cell Transplant on the BMT CTN 0903/AMC-080 and BMT CTN 0803...
  Ariela Noy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma
  Ariela Noy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Safety and Efficacy of Brentuximab Vedotin in Combination with AVD in Stage II-IV HIV-Associated Classical Hodgkin Lymphoma: Results of the Phase 2 Study, AMC 085
  Ariela Noy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Genomic Profiling of Mantle Cell Lymphoma Suggests Poor-Risk Profile Is Present at Diagnosis and Does Not Arise By Tumor Evolution
  Ariela Noy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma
  Ariela Noy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Impact and Safety of Chimeric Antigen Receptor T Cell Therapy in Vulnerable Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
  Ariela Noy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Contemporary Outcomes in HTLV-1-Associated Adult T-Cell Leukemia/Lymphoma: Single-Institution Experience
  Ariela Noy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Randomized Trial of EPOCH-Based Chemotherapy with Vorinostat for Highly Aggressive HIV-Associated Lymphomas: Updated Results Evaluating Impact of Diagnosis-to-Treatm...
  Ariela Noy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Long-Term Follow-up Confirms Durability of Single-Agent Brentuximab Vedotin As Pre-Transplant Salvage for Classical Hodgkin Lymphoma
  Ariela Noy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Multicenter, Open-Label Feasibility Study of Daratumumab with Dose-Adjusted EPOCH in Newly Diagnosed Plasmablastic Lymphoma: AIDS Malignancy Consortium 107
  Ariela Noy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Response-Adapted Therapy with Infusional EPOCH Chemotherapy Plus Rituximab in HIV-Associated, B-Cell Non-Hodgkin's Lymphoma
  Ariela Noy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Expectant Management of Extranodal Marginal Zone Lymphoma of Bronchial-Associated Lymphoid Tissue (BALT)
  Ariela Noy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Retrospective Analysis of Gemcitabine and Oxaliplatin (GemOx)-Based Treatment in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
  Ariela Noy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Phase II, Multicenter Study of High Dose Chemotherapy with Autologous Stem Cell Transplant Followed By Maintenance Therapy with Romidepsin for T-Cell Lymphoma
  Ariela Noy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• High Complete Response Rate Observed with Second-Line Chemo-Immunotherapy with Pembrolizumab and GVD (Gemcitabine, Vinorelbine, and Liposomal Doxorubicin) in Relapsed ...
  Ariela Noy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all